Male Infertility Market - By Type (Test {DNA Fragmentation, Microscopic Examination, Sperm Agglutination}, Treatment), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Drug Stores, Online Pharmacies) - Global Forecast 2024 – 2032

Male Infertility Market Size

Male Infertility Market size was valued at around USD 4 billion in 2023 and is estimated to grow at 4.7% CAGR from 2024 to 2032. Male infertility occurs when a man is unable to impregnate a fertile female partner despite consistent, unprotected intercourse over an extended period.

Typically, it's diagnosed after ruling out potential female infertility causes. Male infertility can stem from various factors, such as sperm production or function issues, structural abnormalities in the reproductive system, hormonal imbalances, genetic predispositions, infections, or environmental influences.
 

The growth in assisted reproductive technologies is a significant driver for the market. The assisted reproductive technologies procedures have revolutionized fertility treatments and have offered hope to couples facing infertility challenges. Assisted reproductive technologies encompass a range of medical procedures designed to facilitate conception when natural conception is not possible or successful. The increasing need for ART stems from factors such as delayed childbearing, rising infertility rates, and advancements in medical technology.
 

According to the Centers for Disease Control and Prevention (CDC), in 2021, fertility clinics in the U.S. performed 413,776 assisted reproductive technologies cycles, resulting in 91,906 live births and 97,128 live-born infants, with 167,689 cycles dedicated to egg or embryo banking for future use. Therefore, this underscore assisted reproductive technology’s pivotal role in helping individuals achieve parenthood despite reproductive challenges.
 

Furthermore, advancements in diagnostic technologies, growth in assisted reproductive technology, which is estimated to reach USD 62.8 billion by 2032, increasing research and development in fertility treatments, rising awareness and education, are the promoting factors advancing the growth of the market.
 

Male Infertility Market Trends

Advancements in diagnostic technologies for male infertility have revolutionized the field, offering unprecedented insights into the complexities underlying reproductive health. From enhanced semen analysis techniques to sophisticated genetic testing and AI-driven diagnostics, these innovations are reshaping how clinicians diagnose and treat male infertility.
 

• Sperm DNA fragmentation testing assesses the integrity of sperm DNA. High levels of fragmentation can indicate sperm damage that may impair fertility or increase the risk of miscarriage. This testing provides crucial insights into male infertility beyond traditional semen analysis, allowing for targeted treatment strategies such as antioxidants or lifestyle modifications to improve sperm quality.
   
• Advances in genetic testing, including karyotyping and Y chromosome microdeletion analysis, help identify genetic abnormalities that can contribute to infertility, providing insights for personalized treatment.
   
• Further, imaging modalities, including scrotal ultrasound and magnetic resonance imaging (MRI), play crucial roles in diagnosing anatomical abnormalities such as varicoceles, cryptorchidism, or congenital defects that may impair sperm production or transport. These technologies aid in planning surgical interventions or medical treatments aimed at restoring fertility, thereby contributing to market growth.
   

Male Infertility Market Analysis

Based on type, the market is segmented into test and treatment. Further test segment is divided into DNA fragmentation technique, oxidative stress analysis, microscopic examination, sperm agglutination, computer assisted semen analysis, sperm penetration assay, and other tests. Treatment segment is bifurcated into medication and ART & varicocele surgery reagents & kits. The treatment segment of the market is forecasted to reach USD 2.1 billion by 2032.
 

• Male infertility results from various underlying medical conditions, such as hormonal imbalances, infections, or genetic disorders. Treatments target these specific conditions to restore normal reproductive function.
   
• The development of new pharmacological treatments presents another significant advantage. Hormonal therapies, antioxidants, and medications targeting specific causes of infertility such as infections or hormonal imbalances have shown promising results. These treatments can improve sperm quality, count, and motility, enhancing natural conception chances or the success rate.
   

Infertility treatments contribute to the broader field of reproductive medicine, advancing knowledge and research. Successful treatments and outcomes provide valuable data that can be used to refine existing methods and develop new, more effective therapies.
 

Based on distribution channel, the male infertility market is segmented into hospital pharmacies, retail pharmacies and drug stores, and online pharmacies. The hospitals pharmacies segment accounted for USD 2.1 billion in 2023.
 

• Hospital pharmacies have access to a wide range of fertility medications, including gonadotropins, androgens, anti-estrogens, and antioxidants. They ensure availability and timely dispensation of these medications, which is critical for optimizing fertility treatment outcomes in men.
   
• Some hospital pharmacies support specialized fertility testing and therapies by providing access to diagnostic kits & reagents, fertility preservation medications for sperm cryopreservation, and supportive care medications. This comprehensive support facilitates the full spectrum of male infertility management, from diagnosis to treatment and beyond.
   
• Hospital pharmacies adhere to stringent quality assurance and safety standards in medication handling, storage, and dispensation. They ensure that fertility medications are stored under appropriate conditions to maintain potency and minimize risks of contamination or adverse effects.

The growth of the male infertility market in the U.S., projected to reach USD 2.2 billion by 2032.
 

• The U.S. is at the forefront of technological innovations in reproductive medicine and male infertility treatment. This includes advancements in sperm DNA fragmentation testing, computer-assisted semen analysis (CASA), genetic testing, and imaging modalities, enabling precise diagnosis and personalized treatment planning.
   
• The regulatory framework in the U.S., overseen by the Food and Drug Administration (FDA), ensures rigorous evaluation and approval of fertility treatments, medications, and diagnostic tools. This regulatory oversight enhances patient safety, promotes quality standards in infertility care, and instills confidence in the effectiveness of available treatments.
   

The male infertility market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• The UK is renowned for its medical education and research institutions, fostering a strong foundation in reproductive medicine and male infertility. Academic centers and research facilities conduct cutting-edge research and clinical trials aimed at advancing treatment options and improving outcomes for infertility patients.
   
• The National Health Service (NHS) provides healthcare coverage to residents of the UK, including fertility services. This includes access to initial consultations, diagnostic tests, and some fertility treatments, reducing financial barriers for patients seeking infertility evaluation and management.
   

Japan male infertility market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Japan maintains stringent regulatory standards for medical devices and fertility treatments, ensuring safety, efficacy, and quality in infertility care. The Pharmaceutical and Medical Devices Agency (PMDA) oversees the approval and monitoring of reproductive technologies and treatments, instilling confidence in patients and healthcare providers.
   
• In Japan, there is generally high cultural acceptance and support for seeking medical assistance for infertility. This cultural openness encourages individuals and couples to seek early diagnosis and treatment for fertility issues, reducing stigma and promoting proactive healthcare-seeking behaviors.
   

The male infertility market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• Fertility clinics in Saudi Arabia prioritize patient education and counseling, providing information on infertility causes, treatment options, and lifestyle factors affecting fertility. This empowers patients to make informed decisions and actively participate in their treatment journey.
   

Male Infertility Market Share

The male infertility sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative infertility therapies leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes. Smaller players focus towards offering male infertility therapies at lower prices, to compete with established players.
 

Male Infertility Market Companies

Some of the eminent market participants operating in the male infertility industry include:

• Andrology Solutions
• ASKA Pharmaceutical Co., Ltd.
• AdvaCare Pharma
• Bayer AG
• CinnaGen Co.
• CaerusBiotech
• Endo International plc
• HalotechDNA
• Intas Pharmaceuticals Ltd.
• Merck KGaA
• Sanofi
• SCSA Diagnostics, Inc
• The Cooper Companies, Inc.
• Vitrolife Group
• Zydus Lifesciences Limited           
            

Male Infertility Industry News:

• In December 2021, The Cooper Companies, Inc. announced that it has completed the acquisition of Generate Life Sciences, that provides fertility cryopreservation services. This acquisition benefited the company by expanding its portfolio in reproductive health services and enhancing its market presence in fertility and regenerative medicine.
   

The male infertility market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Test
  • DNA fragmentation technique
  • Oxidative stress analysis
  • Microscopic examination
  • Sperm agglutination
  • Computer assisted semen analysis
  • Sperm penetration assay
  • Other tests
• Treatment
  • Medication
  • ART & varicocele surgery reagents & kits

Market, By Distribution Channel

• Hospitals pharmacies
• Retail pharmacies and drug stores
• Online pharmacies

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa